The anxiolytic effects and excretion of cannabinoids in humans

This study is divided into three parts. The first part aimed to investigate the cannabidiol anxiolytic effect in treatment-naïve individuals with social anxiety disorder through simulation of public speaking. The second part evaluated healthy subjects' anxiety during a public speaking test following a high rimonabant oral dose, to understand better the possible pharmacological approaches for anxiety disorder treatment. Finally, the third part aimed to monitor cannabinoid blood concentrations during sustained abstinence from chronic daily cannabis smoking. These findings can extend our knowledge on medical use of cannabinoids and impact development of per se laws to reduce morbidity and mortality from cannabis-impaired driving.

Autorentext

Mateus M. Bergamaschi completed his PhD in toxicology with honors from the University of Sao Paulo, Brazil in 2012. His research, conducted at the University of Sao Paulo and the National Institute on Drug Abuse (Baltimore, USA), focused on cannabinoids quantification in human specimens and anxiolytic effects of cannabidiol in humans.